MSX-122 _CXCR4 Antagonist - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMSX-122Cat. No.: HY-13696CAS No.: 897657-95-3分式: CHN分量: 292.34作靶点: CXCR作通路: GPCR/G Protein; Immunology/Inflammation储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 4 mg/mL (13.68 mM; Need ul

2、trasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 3.4207 mL 17.1034 mL 34.2067 mL5 mM 0.6841 mL 3.4207 mL 6.8413 mL10 mM 0.3421 mL 1.7103 mL 3.4207 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，

3、适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 0.4 mg/mL (1.37 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 0.4 mg/mL (1.37 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 0.4 mg/mL (1.37 mM); C

4、lear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 MSX-122种可服的 CXCR4 的部分拮抗剂，抑制 CXCR4/CXCL12 相互作，IC50 值约为 10 nM。MSX-122 具有抗炎和抗转移的活性。IC50 & Target CXCR4/CXCL12-10 nM (IC50)体外研究 MSX-122 is a partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC50 of

5、-10 nM. MSX-122 shows no inhibition on cAMP reduction mediated by their corresponding ligands CCR3/CCL5 andCCR5/CCL5. MSX-122 (100 nM) potently blocks invasion of 78% MDA-MB-231 cells. However, MSX-122does not suppress T-tropic HIV infection and is inactive in calcium flux assay 1.体内研究 MSX-122 (10 m

6、g/kg, i.p.) blocks inflammation induced by carrageenan and lung fibrosis induced bybleomycin in mice. MSX-122 (4 mg/kg, i.p., daily) blocks metastasis in an experimental animal model ofbreast cancer metastasis. Furthermore, MSX-122 (10 mg/kg i.p., daily) significantly decreases the numbersof hepatic

7、 micrometastases 1.PROTOCOLAnimal Mice 1Administration 1 Six- to eight-week-old female nude mice are given injections of 1.5106 MDA-MB-231 breast cancer cellsmixed with the compound (1 M, less than 5 min preincubation) through the tail vein (10/group). From thefollowing day, mice in the treated grou

8、p are given 4 mg/kg MSX-122ms (salt form) daily by i.p. injection. Theanimals are sacrificed 35 days after the tumor cell injection. Whole lung tissues are harvested and sectionedfor real-time RT-PCR for human CXCR4 and H&E histostaining to evaluate the metastatic tumor area in fivefields per sectio

9、n microscopically. These experiments are repeated once more to confirm the results. For thehead and neck cancer animal model, metastatic subclones of 686LN-Ms cells are injected in the same wayas MDA-MB-231 cells. 18FFDG-PET is performed. For the uveal melanoma micrometastasis mouse model,on day 0,

10、each mouse is inoculated with 1106 wild-type OMM2.3 cells expressing HGF/TGF-/CXCR4/MMP2 into the posterior chamber of right eye. On day 3, mice are treated with 10 mg/kg MSX-122 in0.1 mL volume of 45% CD daily by i.p. injection, whereas the control mice are injected with 0.1 mL 45% CDonly. On day 7

11、, eyes with tumor are enucleated. The growth of tumor is checked by histological methods. Onday 28, hepatic tissues are collected and fixed in 10% formalin, processed, H&E stained, and the number ofhepatic micrometastases is counted under microscope. Six sections through the center of the liver arem

12、icroscopically examined for the presence of micrometastases ( 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Liang Z, et al. Development of a unique small molecule modulator of CXCR4. PLoS One. 2012;7(4):e34038.McePdfHeight2/2 Master of Small Molecules 您边的抑制剂师www.MedChemECaution: